Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
Recruiting · NCT06623110 · Registry updated 2026-04-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease | High-Risk Oral Precancerous Disease | Recruiting | Phase 2 | 2026-04-23 | NCT06623110 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Glenn J. Hanna | 3 |
| Replimune, Inc. | 14 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 511 |
| Dana-Farber Cancer Institute | Boston | United States | 68 |